1. INTRODUCTION
Circulating Tumor Cells
Metastasis is the most common cause of cancer-related death in patients with solid tumors. A considerable body of evidence indicates that tumor cells are shed from a primary and metastatic tumor mass at different stages of malignant progression. These break-away circulating tumor cells (CTCs) 1, 2 enter the bloodstream and travel to different tissues of the body as a crucial route for cancer spreading. The current gold standard for diagnosing tumor status requires invasive biopsy, followed by pathological analysis. Unlike tumor biopsies that can be constrained by problems such as sampling bias, CTCs are regarded as the "liquid biopsy" 3 of the tumor, providing convenient access to all disease sites, including the primary tumor and fatal metastases. In addition to conventional diagnostic imaging and serum marker detection, detecting and characterizing CTCs in patient blood provides an opportunity for early diagnosis of cancer metastasis. To address this unmet need, there have been significant research endeavors, especially in the fields of chemistry, materials science, and bioengineering, devoted to developing CTC detection, isolation, and characterization technologies. However, identifying CTCs in blood samples has been technically challenging due to the extremely low abundance (a few to hundreds per milliliter) of CTCs among a large number (10 9 mL −1 ) of hematologic cells.
Existing CTC Enrichment Technologies and Their Limitations
The most widely used CTC detection assays are summarized in the following. (i) Immunomagnetic separation: these methods utilize capture agent-labeled magnetic beads to either positively select 4, 5 CTCs using a cell surface marker, (i.e., anti-epithelial cell adhesion molecule (EpCAM)) or negatively deplete white blood cells (WBCs) using anti-CD45. CellSearch assay 4, 5 is the only FDA-cleared CTC diagnostic technology for metastatic breast, prostate, and colorectal cancer. Recently, several sophisticated systems (e.g., MagSweeper, 6 IsoFlux, 7 and VerIFAST 8 ) have been developed to further improve the detection speed and efficiency. In parallel, Massachusetts General Hospital team's iChip 9 applies the negative depletion mechanism and has attracted significant attention. (ii) Flow cytometry: Although flow cytometry 10 is one of the most mature technologies for analyzing of subpopulations of cells, the flow-based methodology is unable to provide the CTCs' morphological information to meet the gold standard set by pathologists. An improved method, 11 known as ensemble-decision aliquot ranking, was developed to address this weakness. (iii) Microfluidic chips: Several microfluidic technologies 12−14 were developed to achieve higher capture efficiency. However, a majority of these microfluidic CTC technologies suffer from depth of field issues due to the vertical depths of device features (e.g., micropillars 12 or herringbones 14 ) . Multiple cross-sectional scans are required in order to avoid out-of-focus or superimposed micrographs. (iv) CTC filters: Filter-based approaches 15, 16 have been established to trap CTCs according to their sizes. Several commercial products, e.g., Clearbridge 15 and RareCell, 16 are now available on the market. Nevertheless, concerns regarding missing small CTCs have been raised. (v) Other methods: There are review articles 17, 18 where side-by-side comparisons of a wide collection of CTC detection technologies are presented. Although the existing technologies have demonstrated their capacities for efficient CTC detection, challenges remain in (i) establishing a translational pipeline, where a joint effort between researchers and clinicians can be devoted to clinical validation and FDA approval and (ii) most importantly recovering CTCs with improved purity, viability, 19 and molecular integrity 20 in order to enable subsequent molecular and functional analyses. It is conceivable that the CTC-derived molecular signatures and functional readouts can provide significant insight into tumor biology during the critical window where treatment intervention could actually make the difference.
Evolution of NanoVelcro Cell-Affinity Assays
In contrast to existing CTC detection technologies, our team at UCLA pioneered a unique concept of the "NanoVelcro" cellaffinity assay, in which capture agent-coated nanostructured substrates 21−24 were utilized to immobilize CTCs with high efficiency. Through continuous evolution, three generations (gens) of NanoVelcro chips have been established for different clinical utilities. The first-gen NanoVelcro chip, 25−27 composed of a silicon nanowire substrate (SiNS) and an overlaid microfluidic chaotic mixer, was created for CTC enumeration. Side-by-side validation studies using clinical blood samples suggested that the sensitivity of first-gen NanoVelcro chip outperforms that of CellSearch assay. In conjunction with the use of laser microdissection (LMD) techniques, the second-gen NanoVelcro chip 28, 29 with a transparent polymer nanosubstrate was developed for single-CTC isolation. The individually isolated CTCs can be subjected to single-CTC genotyping (e.g., Sanger sequencing and next-generation sequencing, NGS) to verify the CTC's role as tumor liquid biopsy. Created by grafting thermoresponsive polymer brushes onto SiNS, third-gen NanoVelcro chips 30 have demonstrated the capture and release of CTCs at 37 and 4°C, respectively. The temperaturedependent conformational changes of polymer brushes can effectively alter the accessibility of the capture agent on SiNS, allowing for rapid CTC purification with desired viability and molecular integrity. In this Account, we summarize the continuous development of these NanoVelcro CTC assays and their potential applications in oncology clinics.
Nanostructured Substrates for Cell Biology
It has been long documented that nanoscale components present in the tissue microenvironment, including the extracellular matrix (ECM) and cell-surface structures (e.g., microvilli) provide structural and biochemical support that regulates cellular behaviors and fates, including adhesion, migration, communication, differentiation, and viability. Inspired by these nanoscale interactions, researchers have been developing nanostructureembedded substrates, which mimic the features and dimensions of the ECM, in order to understand how different nanosubstrates affect cells and ultimately control cellular behaviors for potential biomedical applications. 31−33 Different from the existing studies, the idea behind NanoVelcro CTC assays is to exploit the use of nanostructured substrates for detection, isolation, and characterization of CTCs.
PROOF-OF-CONCEPT DEMONSTRATION OF
NanoVelcro CELL-AFFINITY SUBSTRATES 2.1. Stationary NanoVelcro CTC Assay
The working mechanism (Figure 1a ) of NanoVelcro cell-affinity substrates 21−24 mimics that of Velcro: when the two fabric strips of a Velcro fastener are pressed together, tangling between the hairy surfaces on two strips leads to enhanced binding. The proof-of-concept demonstration of the NanoVelcro cell-affinity assay 21 lies in the use of a SiNS, which allows for Velcro-like interactions 34 between the SiNS and nanoscale cell-surface components. Here, anti-EpCAM was grafted onto the SiNS as the capture agent, conferring specificity to such a cell-affinity assay for recognizing CTCs and resulting in improved cellcapture affinity compared with that of an unstructured (i.e., flat silicon) substrate (Figure 1b) . The anti-EpCAM grafted SiNS was fabricated through three continuous steps ( Figure 1c ): (i) introduction of densely packed silicon nanowires onto a silicon wafer, (ii) silane treatment and covalent conjugation of streptavidin onto the SiNS, and (iii) grafting of biotinylated anti-EpCAM onto the streptavidin-coated SiNS. Through comprehensive optimization, an optimal condition was obtained for performing cell capture on whole blood samples in a stationary device setting. SEM characterization of CTCs on both SiNSs ( Figure 1d ) and flat Si substrates (Figure 1e ) revealed that there were many interdigitated cell-surface components on the SiNS, supporting the proposed NanoVelcro working mechanism. Generally, NanoVelcro cell-affinity substrates are capable of capturing CTCs from artificial blood samples with about 40− 70% efficiency.
General Applicability NanoVelcro CTC Substrates
In addition to SiNS-based nanosubstrates, we have also adopted different fabrication approaches to incorporate various nanomaterials into NanoVelcro substrates. By an eletrospinning process, horizontally oriented TiO 2 nanofibers were deposited onto glass slides. After anti-EpCAM conjugation, enhanced CTC capture efficiency was observed for the resulting TiO 2 nanofiberembedded NanoVelcro substrates, 23 where the densities of TiO 2 nanofibers affected their CTC-capture performance. Alternatively, an electrochemical method was employed to deposit organic conducting polymer (i.e., PEDOT) nanodots 22 onto ITO-coated glass substrates. Carboxylic groups on PEDOT backbones allow for convenient conjugation with anti-EpCAM, and an enhanced capture performance observed for the nanodotembedded NanoVelcro substrates was determined by the sizes and densities of the nanodots. Recently, a new approach 24 combining chemical oxidative polymerization and a modified PDMS transfer printing technique was established for introducing highly regular PEDOT nanorods onto glass substrates for CTC capture. Given the outstanding electrical transport properties, inherent biocompatibility, and manufacturing flexibility of PEDOT, we foresee that these PEDOT-based NanoVelcro substrates will be integrated with downstream electrical sensing and phenotyping after capturing CTCs.
Besides our own attempts, there has been extensive research devoted to testing different nanostructured materials for capturing CTCs and other types of rare cells. Since our proofof-concept publication 21 40 and other nanomaterials, 41, 42 were deposited on cell-capture substrates to show enhanced cell-capture performance. Both our work and that of others summarized above provide very solid support for the general applicability of NanoVelcro cell-affinity assays and their potential for cell-sorting applications. On the basis of the stationary NanoVelcro cell-affinity substrates, 21−24 we foresaw that further improvement on capture performance could be achieved by increasing the contact frequency between CTCs and nanosubstrates. With the incorporation of an overlaid PDMS chaotic mixer 43 onto a lithographically patterned NanoVelcro substrate (Figure 2a,b) , we developed first-gen NanoVelcro chips. 25 When a blood sample containing CTCs flows through the device, the herringbone microstructures on the roof of the chaotic mixer induce 43 vertical flows in the microchannel, resulting in an enhanced cell−substrate contact frequency. Validation studies using artificial blood samples (i.e., cancer cell-spiked blood) reveal that this CTC assay exhibits >85% cell-capture performance. In parallel our laboratory has also established a three-color immunocytochemistry (ICC) protocol 44 for parallel staining of 4′,6-diamidino-2-phenylindole (DAPI), anti-CD45, and anticytokeratin (CK) to identify nanosubstrate-immobilized CTCs. Single-cell image cytometry data (Figure 2c,d ) covering CK/ CD45 expression and CTC footprint sizes can be used to identify CTCs from nonspecifically captured WBCs and cellular debris.
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Clinical Utility of First-Gen NanoVelcro Chips
To assess the performance of first-gen NanoVelcro chips in a clinical setting, we conducted side-by-side analytical validation studies between NanoVelcro CTC chips and CellSearch assay. The blood samples were collected from prostate cancer patients with different disease severities. Figure 2d shows fluorescence micrographs of two CTCs isolated from a prostate cancer patient's blood (1.0 mL). In 17 out of 26 clinical blood samples (Figure 3a) , first-gen chips exhibited 25 significantly greater sensitivity and superior dynamic range in CTC enumeration. It is known that the clinical utility of CellSearch assay is constrained by its high blood consumption (7.5 mL), poor sensitivity, and dynamic range. We envision that the great performance observed for first-gen NanoVelcro chips will open up opportunities for (i) better monitoring of disease progression and treatment response and (ii) detecting CTCs at a relatively early stage of disease. Continuous improvement of first-gen NanoVelcro CTC chips has led to a device configuration 26 with a smaller device footprint, paving the way for a cost-efficient CTC enumeration assay that can benefit more cancer patients. The validation studies 26 were jointly conducted by the Uro-Oncology teams at both UCLA Hospital and Cedars-Sinai Medical Center. Forty prostate cancer patients (32 with metastatic disease and 8 with localized disease) were recruited, and CTCs were identified in all 40 patients. We further performed follow-up measurements in these patients over the courses of different treatments. As a result of the NanoVelcro chips' high sensitivity, we found that patients responding to the given therapies have a significant negative change in their CTC numbers. In the index patient, we performed serial measurements for up to 460 days, during which multiple therapies were given with variable responses (Figure 3b ). CTC counts faithfully represented the initial response and subsequent failures. However, we observed a CTC−PSA disagreement when his disease was stabilized by docetaxel therapy. The patient's CTC numbers remained low despite PSA progression when bone scan confirmed his stable disease. This case indicates that CTC number measured by NanoVelcro CTC chip may be a more reliable biomarker in the clinical assessment of prostate cancer. In addition to prostate cancer, our studies toward applying NanoVelcro chips for different types of cancer (e.g., breast, lung, and pancreatic cancer, as well as melanoma) are making continuous progress.
An Alternative Capture Agent, Aptamer
Anti-EpCAM remains the most commonly used CTC capture agent for the majority of epithelial origin solid tumors. Due to the poor stability and high cost of antibody, the dissemination and translation of CTC-based diagnostics can be constrained especially in a low-resource environment. This limitation can be addressed by replacing anti-EpCAM with aptamers, which were generated through an in vitro cell-SELEX (systematic evolution of ligands by exponential enrichment) process targeting a specific type of cancer cells. Recently, we were able to produce two single-stranded DNA aptamers via cell-SELEX 45 processes in the presence of A549 non-small-cell lung cancer (NSCLC) cells. We demonstrated 27 that the aptamer-grafted NanoVelcro chip (Figure 4 ) is capable of not only capturing NSCLC CTCs from blood with high efficiency but also recovering the nanosubstrate-immobilized CTCs upon enzymatic treatment.
Recently, an interesting phenomenon 46 that capture-agent free nanosubstrates on glass slides exhibit a differential affinity to cancer cells rather than WBCs was reported. Although this differential affinity is potentially applicable for CTC detection, concerns have been raised for the lack of understanding of the molecular and cellular mechanism that governs such a differential affinity. Further experimental data supporting their utility in clinical setting remain to be provided. 
SECOND-GENERATION NanoVelcro-LMD TECHNOLOGY FOR SINGLE-CTC ISOLATION
The development of first-gen NanoVelcro chips has led to a highly sensitive CTC enumeration technology that has demonstrated its clinical utility for monitoring disease progression and reporting treatment responses. To pave the way toward molecular analysis of CTCs, we developed secondgen NanoVelcro-LMD technology 28, 29 (Figure 5a ) by coupling LMD techniques with a transparent nanosubstrate covered with poly(lactic-co-glycolic acid) (PLGA) nanofibers. Unlike the SiNS used in the first-gen chips, the transparent PLGA nanosubstrates within NanoVelcro-LMD technology 28, 29 allows single-CTC identification and isolation, followed by a wide range of molecular analyses (e.g., RT-PCR, Sanger sequencing, and NGS).
Preparation of PLGA NanoVelcro Chips
The PLGA NanoVelcro substrates 28, 29 were prepared by depositing electrospun PLGA nanofibers onto a commercial LMD slide (i.e., a regular microscope slide covered with a 1.2-μm-thick polymer membrane, Figure 5a ). After covalently attaching streptavidin onto the PLGA nanofibers, conjugation of biotinylated antibodies confers capture specificity to PLGA NanoVelcro substrates (Figure 5b ,c) to identify CTCs from whole blood samples.
NanoVelcro-LMD Technology, Followed by Mutational Analysis
We first applied NanoVelcro-LMD technology to isolate 28 single melanoma CTCs (Figure 5d ) for detecting a signature oncogenic mutation (i.e., BRAF V600E ), which is present in 60% of melanomas and has been targeted by specific inhibitors (e.g., vemurafenib). Here, a melanoma-specific anti-CD146 was used as the capture agent. To validate the clinical utility of NanoVelcro-LMD technology, we then performed single-CTC isolation and genotyping using peripheral blood samples collected from several stage-IV melanoma patients, whose melanomas have been previously characterized to contain BRAF V600E . The individually isolated melanoma CTCs were subjected to whole genome amplification (WGA) and PCR targeting BRAF, and Sanger sequencing was then employed to detect the BRAF V600E mutation in the melanoma CTCs. Notably, the Sanger sequencing data obtained for the BRAF V600E mutation in single melanoma CTCs (Figure 5e ) displayed a strong signalto-noise ratio. In contrast, varying levels of sequencing noise and BRAF V600E signals were often encountered when biopsied melanoma tissues were sequenced.
The same single-CTC genotyping approach has also been used for different solid tumors with specific signature oncogenic mutations. For example, using anti-EpCAM as capture agent, we were able to isolate single CTCs from artificial and clinical blood samples. Genotyping of the individually isolated pancreatic CTCs disclosed a KRAS G12V mutation (Figure 5f ), consistent with that found in patients' tumors.
NanoVelcro-LMD Technology, Followed by Whole Exome Sequencing
Due to frequent cell loss caused 28 by the static charge during collection processes, we replaced 29 the LMD technology with a modified version, that is, laser capture microdissection (LCM). The LCM technology prevented the cell loss by employing an IR-laser to melt the LCM cap, dropping down a "sticky finger" for adhering onto laser-dissected NanoVelcro substrate (Figure 6a ). This system allows for isolation of single CTCs from patients with advanced prostate cancer suitable for NGS to detect mutations in a broader mutational landscape (Figure 6b,c) . Prostate cancer is known for its long natural course of up to 10− 15 years in most cases. The combined use of single-CTC isolation and NGS can be used to monitor the evolution of tumor heterogeneity 20 over time. Beyond single-CTC exome sequencing, our continuous efforts will be devoted to exploring the Figure 7 . Operational mechanism of the thermoresponsive NanoVelcro CTC substrate for capturing and releasing CTCs at 37 and 4°C, respectively. The temperature-dependent conformational changes of polymer brushes effectively alter the accessibility of anti-EpCAM on NanoVelcro substrates. second-gen NanoVelcro-LCM/LMD technology in conjunction with advanced NGS including whole genome sequencing, transcriptomic analysis by RNA sequencing, and epigenetic studies. The information will help to understand the tumor heterogeneity and clonal evolution, as well as provide real-time monitoring of patients' disease progression and response to specific treatments.
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THIRD-GENERATION THERMORESPONSIVE NanoVelcro CHIPS
As the molecular characterization 20 and functional analysis 19 of CTCs are increasingly conducted, there is an urgent need to isolate CTCs with higher efficiency, higher cell quality, and less technical demand. Although the second-gen NanoVelcro-LCM approach 32, 33 possesses a great precision in single-CTC isolation, it suffers from a labor-consuming process and poor viabilities of the isolated CTCs. The third-gen thermoresponsive NanoVelcro chip 30 was developed to address these issues. Created by grafting thermoresponsive polymer brushes 47 (i.e., poly(N-isopropylacrylamide, PIPAAm) onto SiNS, thermoresponsive NanoVelcro chips ( Figure 7 ) can capture and release CTCs at 37 and 4°C, respectively. The uniqueness of our idea is that the temperaturedependent conformational changes of polymer brushes can effectively alter the accessibility of the capture agent on the NanoVelcro, allowing for rapid CTC purification with desired CTC viability and molecular integrity. More specifically, we strategically introduced biotin groups onto the polymer brushes for conjugation of a CTC-capture agent, anti-EpCAM. At 37°C, anti-EpCAM and hydrophobic domains of the polymer brushes are present on the surfaces of NanoVelcro substrates, enabling CTC capture. When the temperature is reduced to 4°C, the conformational change of the polymer brushes induces an internalization of anti-EpCAM, leading to CTC release. The thermoresponsive NanoVelcro chip exhibited enhanced CTCcapture efficiency, and the majority of the captured cells were successfully released at 4°C with approximately 90% viability.
Our continuous research efforts will be devoted to building a user-interface of third-gen thermoresponsive NanoVelcro chips. The goal is to enable rapid purification of CTCs from whole blood samples, thus paving the way for downstream CTC characterization. In addition to performing CTC molecular analysis, obtaining viable CTCs for ex vivo expansion (i.e., culture) will set the stage for a wide range of applications, e.g., generating CTC-derived cancer lines and in vitro screening for potential therapeutics for individual cancer patients, a promising opportunity for bringing personalized medicine to fruition.
CONCLUSIONS AND FUTURE PERSPECTIVES
Over the past decade, detection, isolation, and characterization of CTCs have been a research focal point that attracts significant attention from broad research disciplines, including oncology, cancer biology, bioengineering, materials science, chemistry, and other related fields. Although a variety of CTC detection technologies have been demonstrated, continuous efforts are needed to acquire translational data in order to benefit cancer patients. Going beyond CTC detection, it is crucial to further develop highly efficient CTC isolation and purification platforms in order to pave the way for the subsequent molecular and functional analyses. Ultimately, the CTC-derived molecular signatures and functional readouts will be able to provide significant insight into tumor biology during the critical window where treatment intervention could actually make the difference.
Based on the unique NanoVelcro working mechanism, our team at UCLA has successfully demonstrated three generations of NanoVelcro CTC chips capable of detecting, isolating, and purifying CTCs from blood samples with high efficiency. In the presence of different capture agents, NanoVelcro CTC chips were used to capture CTCs shed from several types of solid tumors, including prostate, breast, lung, and pancreatic cancer, as well as melanoma. We were able to subject the CTCs isolated by NanoVelcro CTC chips to subsequent molecular analyses, for example, Sanger sequencing and NGS to verify CTC's role as tumor liquid biopsy. Meanwhile, we have been testing the feasibility to culture the purified CTCs in order to pave the way for a wide range of applications that will impact realization of personalized medicine. Our continuous research endeavors will be devoted to translating our discovery in the research laboratory to oncology clinics. 
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